Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.
The long overdue advent of US cut-price oncology drugs is a major theme at this year’s Asco, and Junshi’s toripalimab leads the way.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
Pain drugs look like they could face different outcomes, while targeted cancer agents will have a big month. Two biosimilar decisions also await.